1. Home
  2. PRZO vs PHGE Comparison

PRZO vs PHGE Comparison

Compare PRZO & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$0.71

Market Cap

18.6M

Sector

N/A

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.84

Market Cap

15.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
PHGE
Founded
2014
2015
Country
Israel
United States
Employees
N/A
57
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
15.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
PRZO
PHGE
Price
$0.71
$0.84
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
5.3M
9.3M
Earning Date
03-26-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.25
52 Week High
$2.15
$8.50

Technical Indicators

Market Signals
Indicator
PRZO
PHGE
Relative Strength Index (RSI) 52.37 42.25
Support Level $0.68 $0.41
Resistance Level $0.82 $2.35
Average True Range (ATR) 0.12 0.23
MACD 0.04 0.11
Stochastic Oscillator 35.63 32.61

Price Performance

Historical Comparison
PRZO
PHGE

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: